Dec 12, 2017
Eyevensys Appoints Dr. Patricia Zilliox as Chief Executive Officer
Dec 06, 2017
Uveitis - Market Insights, Epidemiology and Market Forecast - 2025
Nov 29, 2017
Aldeyra Therapeutics Presents Noninfectious Anterior Uveitis Phase 2 Clinical Trial Data to the American Uveitis Society Held at the American Academy of Ophthalmology 2017 Annual Meeting
Nov 28, 2017
The global ophthalmic therapeutics/drugs market is expected to reach USD 35.7 billion by 2025
Nov 09, 2017
Aldeyra Therapeutics Announces Third Quarter 2017 Financial Results
Nov 06, 2017
Ophthalmic Therapeutics Market Size Worth $35.7 Billion by 2025: Grand View Research, Inc.
Oct 25, 2017
Aldeyra Therapeutics Announces Presentation of Results on the Efficacy of ADX-102 in Noninfectious Anterior Uveitis at the American Uveitis Society Held at the American Academy of Ophthalmology 2017 Annual Meeting
Oct 10, 2017
Aldeyra Therapeutics Announces New Data at 2017 Research & Development Day
Sep 13, 2017
Eyevensys Appoints Thierry Bordet Ph.D. as Pre-clinical Director
Sep 12, 2017
Aldeyra Therapeutics Announces Positive Results from Dry Eye Disease Phase 2a Clinical Trial
Sep 04, 2017
Eyevensys Appoints Dr Ronald R. Buggage as Chief Medical Officer
Aug 02, 2017
Uveitis Therapeutics Pipeline Analysis, 2017 - 33 Active Drug Candidates in Different Stages of Development
Jul 25, 2017
Ophthalmic Drugs Market to Reach US$34.3 Billion by 2025: Players Entering Into Co-development Agreements to Enhance Product Portfolio
Jul 21, 2017
AbbVie Receives CHMP Positive Opinion for HUMIRA® (adalimumab) for the Treatment of Pediatric Patients with Chronic Non-infectious Anterior Uveitis